Clinical Trial Update: Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety of adding IMO-2055 to erlotinib plus bevacizumab in second-line non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)
• IMO-2055

Snippet

Sponsor: EMD Serono | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED